| (Values in U.S. Thousands) | Mar, 2016 | Dec, 2015 | Sep, 2015 | Jun, 2015 | Mar, 2015 |
| Sales | 1,548,000 | 1,763,000 | 1,595,000 | 1,429,000 | 1,361,000 |
| Sales Growth | -12.20% | +10.53% | +11.62% | +5.00% | -19.13% |
| Net Income | 145,000 | 95,000 | 309,000 | 280,000 | 272,000 |
| Net Income Growth | +52.63% | -69.26% | +10.36% | +2.94% | -64.35% |
Baxalta Incorporated Common Sto (BXLT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Baxalta Incorporated is a biopharmaceutical company which is engaged in developing, manufacturing and commercializing transformative therapies to treat orphan and underserved disease conditions in hematology, immunology and oncology. Baxalta Incorporated is based in Deerfield, United States.
Fiscal Year End Date: 12/31